Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8370MR)

This product GTTS-WQ8370MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8370MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7703MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ4026MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ10261MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ13679MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ12199MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ11280MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ10135MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ7305MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW